Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Histone deacetylase")

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Origin

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 2474

  • Page / 99
Export

Selection :

  • and

Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?KARAGIANNIS, T. C; EL-OSTA, A.Leukemia. 2007, Vol 21, Num 1, pp 61-65, issn 0887-6924, 5 p.Article

FK228 (depsipeptide) : a HDAC inhibitor with pleiotropic antitumor activitiesKONSTANTINOPOULOS, Panagiotis A; VANDOROS, Gerasimos P; PAPAVASSILIOU, Athanasios G et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 5, pp 711-715, issn 0344-5704, 5 p.Article

Inhibiteurs des histone-désacétylases: la régulation épigénétique sort de l'ombre = Histone deacetylase inhibitors: highlight on epigenetic regulationPECUCHET, N; CLUZEAU, T; THIBAULT, C et al.Bulletin du cancer. 2010, Vol 97, Num 8, pp 917-935, issn 0007-4551, 19 p.Article

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?NOLAN, L; JOHNSON, P. W. M; GANESAN, A et al.British journal of cancer. 2008, Vol 99, Num 5, pp 689-694, issn 0007-0920, 6 p.Article

Histone Deacetylase Inhibitors Promote the Tumoricidal Effect of HAMLETBREST, Patrick; GUSTAFSSON, Mattias; MOSSBERG, Ann-Kristin et al.Cancer research (Baltimore). 2007, Vol 67, Num 23, pp 11327-11334, issn 0008-5472, 8 p.Article

Structure of HDAC3 bound to co-repressor and inositol tetraphosphateWATSON, Peter J; FAIRALL, Louise; SANTOS, Guilherme M et al.Nature (London). 2012, Vol 481, Num 7381, pp 335-340, issn 0028-0836, 6 p.Article

HDAC inhibitor-based therapies and haematological malignancySTIMSON, L; WOOD, V; KHAN, O et al.Annals of oncology. 2009, Vol 20, Num 8, pp 1293-1302, issn 0923-7534, 10 p.Article

HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic painDENK, Franziska; WENLONG HUANG; MCMAHON, Stephen B et al.Pain (Amsterdam). 2013, Vol 154, Num 9, pp 1668-1679, issn 0304-3959, 12 p.Article

Identification of type-specific anticancer histone deacetylase inhibitors: road to successNOUREEN, Nighat; RASHID, Hamid; KALSOOM, Saima et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 4, pp 625-633, issn 0344-5704, 9 p.Article

Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseasesGWANG HYEON EOM; HYUN KOOK.Pharmacology & therapeutics (Oxford). 2014, Vol 143, Num 2, pp 168-180, issn 0163-7258, 13 p.Article

Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781BANUELOS, Carmen A; BANATH, Judit P; MACPHAIL, Susan H et al.Clinical cancer research. 2007, Vol 13, Num 22, pp 6816-6826, issn 1078-0432, 11 p., 1Article

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβMARCHION, Douglas C; BICAKU, Elona; TURNER, Joel G et al.Clinical cancer research. 2005, Vol 11, Num 23, pp 8467-8475, issn 1078-0432, 9 p.Article

Association of SIRT1 gene variation with visceral obesityPEETERS, Armand V; BECKERS, Sigri; VERRIJKEN, An et al.Human genetics. 2008, Vol 124, Num 4, pp 431-436, issn 0340-6717, 6 p.Article

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDACMITHRAPRABHU, Sridurga; KHONG, Tiffany; JONES, Simon S et al.British journal of haematology. 2013, Vol 162, Num 4, pp 559-562, issn 0007-1048, 4 p.Article

Regulation of the HIF-1α stability by histone deacetylasesKIM, Se-Hee; JEONG, Joo-Won; JEONG AE PARK et al.Oncology reports. 2007, Vol 17, Num 3, pp 647-651, issn 1021-335X, 5 p.Article

Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinasePARK, Jung-Hyun; JONG, Hyun-Soon; SANG GYUN KIM et al.Journal of molecular medicine (Berlin. Print). 2008, Vol 86, Num 1, pp 117-128, issn 0946-2716, 12 p.Article

Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expressionMATSUOKA, Hideaki; FUJIMURA, Takao; HAYASHI, Masako et al.Biochemical pharmacology. 2007, Vol 74, Num 3, pp 465-476, issn 0006-2952, 12 p.Article

Towards Histone Deacetylase Inhibitors as New Antimalarial DrugsANDREWS, Katherine T; TRAN, Thanh N; FAIRLIE, David P et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 24, pp 3467-3479, issn 1381-6128, 13 p.Article

Class II histone deacetylases are associated with VHL-lndependent regulation of hypoxia-inducible factor 1αQIAN, David Z; KACHHAP, Sushant K; COLLIS, Spencer J et al.Cancer research (Baltimore). 2006, Vol 66, Num 17, pp 8814-8821, issn 0008-5472, 8 p.Article

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignanciesYONG, W. P; GOH, B. C; LIM, D et al.Annals of oncology. 2011, Vol 22, Num 11, pp 2516-2522, issn 0923-7534, 7 p.Article

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primatesWARREN, Katherine E; MCCULLY, Cindy; DVINGE, Henrik et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 3, pp 433-437, issn 0344-5704, 5 p.Article

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumoursRAZAK, Ara; HOTTE, S. J; ZHU, J et al.British journal of cancer. 2011, Vol 104, Num 5, pp 756-762, issn 0007-0920, 7 p.Article

Histone deacetylase inhibition as an anticancer telomerase-targeting strategyRAHMAN, Ruman; GRUNDY, Richard.International journal of cancer (Print). 2011, Vol 129, Num 12, pp 2765-2774, issn 0020-7136, 10 p.Article

Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors : Histone Deacetylase InhibitorsBUTLER, Kyle V; KOZIKOWSKI, Alan P.Current pharmaceutical design. 2008, Vol 14, Num 6, pp 505-528, issn 1381-6128, 24 p.Article

Histone deacetylase inhibitors in the treatment for multiple myeloma : PIH: Basic and Clinical Updates in Multiple MyelomaHIDESHIMA, Teru; ANDERSON, Kenneth C.International journal of hematology. 2013, Vol 97, Num 3, pp 324-332, issn 0925-5710, 9 p.Article

  • Page / 99